Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.
Xuan ChenAlison H AffinatiYungchun LeeAdina F TurcuNorah Lynn HenryElena SchiopuAngel QinMegan OthusDan ClauwNithya RamnathLili ZhaoPublished in: Diabetes care (2022)
The risk of ICI-T1DM is associated with the type of ICI therapy, patient age, and preexisting non-T1DM diabetes. These data may help guide risk assessment and screening practices for patients during ICI therapy.
Keyphrases
- type diabetes
- glycemic control
- risk assessment
- end stage renal disease
- cardiovascular disease
- ejection fraction
- newly diagnosed
- primary care
- chronic kidney disease
- healthcare
- peritoneal dialysis
- prognostic factors
- stem cells
- insulin resistance
- electronic health record
- human health
- heavy metals
- big data
- patient reported outcomes
- smoking cessation